“Sensitivity of KRAS-Mutated Non-Small Cell Lung Cancer to a Combination of MEK Kinase Inhibitor (Trametinib) and Autophagy Inhibitor (Hydroxychloroquine) in a Tissue Explant Model” (2026) Voprosy onkologii, 72(1), p. OF-2403. doi:10.37469/0507-3758-2026-72-1-OF-2403.